Structure-function relationships of the N-terminus of receptor activity-modifying proteins

British Journal of Pharmacology

Volumn 159, Issue 5, 2010, Pages 1059-1068

  Qi, Tao ^a   Hay, Debbie L ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Adrenomedullin; Amylin; Calcitonin; Calcitonin gene related peptide; Calcitonin receptor; Calcitonin receptor like receptor; Mutagenesis; Receptor activity modifying proteins

Indexed keywords

RECEPTOR ACTIVITY MODIFYING PROTEIN; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; RECEPTOR ACTIVITY MODIFYING PROTEIN 2; RECEPTOR ACTIVITY MODIFYING PROTEIN 3;

CELL TYPE; HUMAN; LIGAND BINDING; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

ALLOSTERIC REGULATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; MEMBRANE PROTEINS; MUTAGENESIS; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, CALCITONIN;

EID: 77949355583     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00541.x     Document Type: Review

References (36)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition (2008 revision). Br J Pharmacol 153 (Suppl. 2): S1-S209.
2. Benítez-Páez A (2006). Sequence analysis of the receptor activity-modifying proteins family, new putative peptides and structural conformation inference. In Silico Biol 6: 467-483.
3. Benítez-Páez A, Cárdenas-Brito S (2008). Dissection of functional residues in receptor activity-modifying proteins through phylogenetic and statistical analyses. Evol Bioinform 4: 153-169.
4. Bomberger JM, Parameswaran N, Hall CS, Aiyar N, Spielman WS (2005). Novel function for receptor activity-modifying proteins (RAMPs) in post-endocytic receptor trafficking. J Biol Chem 280: 9297-9307.
5. Bouschet T, Martin S, Henley JM (2005). Receptor-activity-modifying proteins are required for forward trafficking of the calcium-sensing receptor to the plasma membrane. J Cell Sci 118: 4709-4720.
6. Christopoulos A, Christopoulos G, Morfis M, Udawela M, Laburthe M, Couvineau A et al. (2003). Novel receptor partners and function of receptor activity-modifying proteins. J Biol Chem 278: 3293-3297.
7. Flahaut M, Pfister C, Rossier BC, Firsov D (2003). N-glycosylation and conserved cysteine residues in RAMP3 play a critical role for the functional expression of CRLR/RAMP3 adrenomedullin receptor. Biochemistry 42: 10333-10341.
8. Fraser NJ, Wise A, Brown J, McLatchie LM, Main MJ, Foord SM (1999). The amino terminus of receptor activity modifying proteins is a critical determinant of glycosylation state and ligand binding of calcitonin receptor-like receptor. Mol Pharmacol 55: 1054-1059.
9. Hay DL, Christopoulos G, Christopoulos A, Sexton PM (2006a). Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-l- piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl] -2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors - the role of receptor activity modifying protein 1. Mol Pharmacol 70: 1984-1991.
10. Hay DL, Poyner DR, Sexton PM (2006b). GPCR modulation by RAMPs. Pharmacol Ther 109: 173-197.
11. Heroux M, Hogue M, Lemieux S, Bouvier M (2007). Functional calcitonin gene-related peptide receptors are formed by the asymmetric assembly of a calcitonin receptor-like receptor homo-oligomer and a monomer of receptor activity-modifying protein-1. J Biol Chem 282: 31610-31620.
12. Hilairet S, Belanger C, Bertrand J, Laperriere A, Foord SM, Bouvier M (2001a). Agonist-promoted internalization of a ternary complex between calcitonin receptor-like receptor, receptor activitymodifying protein 1 (RAMP1), and beta-arrestin. J Biol Chem 276: 42182-42190.
13. Hilairet S, Foord SM, Marshall FH, Bouvier M (2001b). Protein-protein interaction and not glycosylation determines the binding selectivity of heterodimers between the calcitonin receptor-like receptor and the receptor activity-modifying proteins. J Biol Chem 276: 29575-29581.
14. Kunz TH, Mueller-Steiner S, Schwerdtfeger K, Kleinert P, Troxler H, Kelm JM et al. (2007). Interaction of receptor-activity-modifying protein 1 with tubulin. Biochim Biophys Acta 1770: 1145-1150.
15. Kusano S, Kukimoto-Niino M, Akasaka R, Toyama M, Terada T, Shirouzu M et al. (2008). Crystal structure of the human receptor activity-modifying protein 1 extracellular domain. Protein Sci 17: 1907-1914.
16. Kuwasako K, Shimekake Y, Masuda M, Nakahara K, Yoshida T, Kitaura M et al. (2000). Visualization of the calcitonin receptor-like receptor and its receptor activity-modifying proteins during internalization and recycling. J Biol Chem 275: 29602-29609.
17. Kuwasako K, Kitamura K, Ito K, Uemura T, Yanagita Y, Kato J et al. (2001). The seven amino acids of human RAMP2 (86-92) and RAMP3 (59-65) are critical for agonist binding to human adrenomedullin receptors. J Biol Chem 276: 49459-49465.
18. Kuwasako K, Kitamura K, Onitsuka H, Uemura T, Nagoshi Y, Kato J et al. (2002). Rat RAMP domains involved in adrenomedullin binding specificity. FEBS Lett 519: 113-116.
19. Kuwasako K, Kitamura K, Nagoshi Y, Cao Y-N, Eto T (2003a). Identi-fication of the human receptor activity-modifying protein 1 domains responsible for agonist binding specificity. J Biol Chem 278: 22623-22630.
20. Kuwasako K, Kitamura K, Uemura T, Nagoshi Y, Kato J, Eto T (2003b). The function of extracellular cysteines in the human adrenomedullin receptor. Hyperten Res 26: 25-31.
21. Kuwasako K, Cao YN, Nagoshi Y, Kitamura K, Eto T (2004). Adrenomedullin receptors: pharmacological features and possible pathophysiological roles. Peptides 25: 2003-2012.
22. Kuwasako K, Kitamura K, Nagata S, Kato J (2008). Functions of the extracellular histidine residues of receptor activity-modifying proteins vary within adrenomedullin receptors. Biochem Biophy Res Commun 377: 109-113.
23. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N et al. (1998). RAMPs regulate the transport and ligand specificity of the calcitonin receptor-like receptor. Nature 393: 333-339.
24. Mallee JJ, Salvatore CA, LeBourdelles B, Oliver KR, Longmore J, Koblan KS et al. (2002). Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem 277: 14294-14298.
25. Morfis M, Tilakaratne N, Furness SGB, Christopoulos G, Werry TD, Christopoulos A et al. (2008). Receptor activity modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors. Endocrinology 149: 5423-5431.
26. Parameswaran N, Spielman WS (2006). RAMPs: the past, present and future. Trends Biochem Sci 31: 631-638.
27. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, BornWet al. (2002). International Union of Pharmacology: XXXII. The mammalian calcitonin gene-related peptides, AM, AMY, and calcitonin receptors. Pharmacol Rev 54: 233-246.
28. Qi T, Christopoulos G, Bailey RJ, Christopoulos A, Sexton PM, Hay DL (2008). Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and amylin receptor function. Mol Pharmacol 74: 1059-1071.
29. Sexton PM, Albiston A, Morfis M, Tilakaratne N (2001). Receptor activity modifying proteins. Cell Signal 13: 73-83.
30. Sexton PM, Poyner DR, Simms J, Christopoulos A, Hay DL (2009). Modulating receptor function through RAMPs: can they represent drug targets in themselves? Drug Discov Today 14: 413-419.
31. Simms J, Hay DL, Wheatley M, Poyner DR (2006). Characterization of the structure of RAMP1 by mutagenesis and molecular modeling. Biophys J 91: 662-669.
32. Simms J, Hay DL, Bailey RJ, Konycheva G, Bailey G, Wheatley M et al. (2009). Structure function analysis of RAMP1 by alanine mutagenesis. Biochemistry 48: 198-205.
33. Steiner S, Muff R, Gujer R, Fischer JA, Born W (2002). The transmembrane domain of receptor-activity-modifying protein 1 is essential for the functional expression of a calcitonin gene-related peptide receptor. Biochemistry 41: 11398-11404.
34. Udawela M, Christopoulos G, Morfis M, Christopoulos A, Ye SY, Tilakaratne N et al. (2006a). A critical role for the short intracellular C terminus in receptor activity-modifying protein function. Mol Pharmacol 70: 1750-1760.
35. Udawela M, Christopoulos G, Tilakaratne N, Christopoulos A, Albiston A, Sexton PM (2006b). Distinct receptor activity-modifying protein domains differentially modulate interaction with calcitonin receptors. Mol Pharmacol 69: 1984-1989.
36. Zumpe ET, Tilakaratne N, Fraser NJ, Christopoulos G, Foord SM, Sexton PM (2000). Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product. Biochem Biophys Res Commun 267: 368-372.